Nowadays, the use of cell membrane-penetrating peptides is part of clinical trials for the treatment of dermatitis, cancer and cardiac failure.
A peptidomimetic containing a fluorescent grouping in the sequence (5/6-carboxyfluorescein) may find application in the pharmaceutical industry and, in particular, facilitate the penetration of therapeutic substances used in anticancer therapy into the nucleus cell.
The active substance, which contains a fluorescent grouping in the sequence (5/6-carboxyfluorescein), is intended for use in the pharmaceutical industry as an ingredient in drugs with a long time to penetrate the nucleus cell, making it possible to accelerate this process.
The developed method allows the introduction of the drug active substance in a more targeted manner, with little risk of destroying a healthy cell. The use of the innovative substance has the positive effect of accelerating the cancer treatment process.
